Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMS-986177 (milvexian) is an investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) which delays the time to clot formation, decreases fibrin incorporation into the clot, and reduces the resistance of clots to fibrinolysis.
Product Name : BMS-986177
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMS-986177 (milvexian) is an investigational, oral factor XIa (FXIa) inhibitor (antithrombotic) which delays the time to clot formation, decreases fibrin incorporation into the clot, and reduces the resistance of clots to fibrinolysis.
Product Name : BMS-986177
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2023
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JNJ-70033093 (milvexian) is a potential first-in-class oral factor XIa (FXIa) inhibitor (anti-thrombotic) being studied for the prevention and treatment of major thrombotic conditions.
Product Name : BMS-986177
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2022
Lead Product(s) : Milvexian
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milvexian
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Milvexian demonstrated efficacy and no increase in bleeding across doses, when compared with enoxaparin, for postoperative venous thromboembolism (VTE) prevention in patients undergoing elective total knee replacement (TKR) surgery.
Product Name : BMS-986177
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2021
Lead Product(s) : Milvexian
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable